Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 24;2(4):454-461.
doi: 10.1016/j.xfre.2021.07.003. eCollection 2021 Dec.

Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate

Amy D DiVasta  1   2   3 , Catherine Stamoulis  1   3 , Jenny Sadler Gallagher  1   2 , Marc R Laufer  2   3   4   5 , Raymond Anchan  2   3   5 , Mark D Hornstein  2   3   5
Affiliations

Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate

Amy D DiVasta et al. F S Rep. .

Abstract

Objective: To estimate the efficacy and safety of a novel nonhormonal therapeutic agent, cabergoline, compared with that of the standard clinical therapy, norethindrone acetate (NETA), for the treatment of endometriosis-associated pain in young women with endometriosis.

Design: Randomized, double-blind, placebo-controlled pilot study.

Setting: Tertiary care center.

Patients: Women (n = 9) with surgically confirmed endometriosis.

Interventions: A random, double-blind assignment to either NETA (5 mg/day) + placebo twice weekly or cabergoline (0.5 mg) twice weekly + placebo daily for 6 months.

Main outcome measures: We collected the measures of pelvic pain and laboratory parameters every 3 months.

Results: We observed a decrease in pain scores and increase in pain relief in women randomized to receive cabergoline, who appeared to show similar or more improvements than women treated with NETA. The serum measures of vascular endothelial growth factor receptor 1 declined over 6 months in those who received cabergoline. Cabergoline was well tolerated, and no serious adverse events occurred.

Conclusions: Safe, effective adjunct treatments are lacking for patients with endometriosis who do not respond to standard care. Because the growth of endometriosis requires angiogenesis, blood vessel growth is an attractive therapeutic target. This pilot study suggests that cabergoline, a vascular endothelial growth factor pathway inhibitor, is an effective therapeutic option for women with chronic pain due to endometriosis. Building upon this investigation, we will conduct larger, randomized trials of cabergoline, advancing research on the best treatments for endometriosis-particularly disease resistant to hormonal therapies.

Clinical trial registration number: clinicaltrials.gov; registration number NCT02542410.

Keywords: Angiogenesis; cabergoline; endometriosis; nonhormonal therapy; norethindrone acetate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in the measurement of pain over 6 months in 9 women randomized to receive either cabergoline or NETA. (A) Pain severity score today. (B) Worst pain severity score in the last 24 hours. (C) Average pain severity score. (D) Worst pain severity score in the last month. NETA = norethindrone acetate.
Figure 2
Figure 2
Changes in the measurement of VEGF-R1 over 6 months in 9 women randomized to receive either cabergoline or NETA. NETA = norethindrone acetate; VEGF-R1 = vascular endothelial growth factor receptor 1.
Supplemental Figure 1
Supplemental Figure 1
Patient recruitment, enrollment, and disposition.
See this image and copyright information in PMC

References

    1. Zondervan K.T., Becker C.M., Missmer S.A. Endometriosis. N Engl J Med. 2020;382:1244–1256. - PubMed
    1. Taylor H.S., Kotlyar A.M., Flores V.A. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. Lancet. 2021;397:839–852. - PubMed
    1. ACOG Committee Opinion. Number 310, April 2005. Endometriosis in adolescents. Obstet Gynecol. 2005;105:921–927. - PubMed
    1. Nothnick W., Alali Z. Recent advances in the understanding of endometriosis: the role of inflammatory mediators in disease pathogenesis and treatment. F1000Research. 2016;5 - PMC - PubMed
    1. Nnoaham K.E., Hummelshoj L., Webster P., d’Hooghe T., de Cicco Nardone F., de Cicco Nardone C., et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011;96:366–373. - PMC - PubMed

Associated data